Request Demo
Last update 16 May 2025
WT-1 analog peptide vaccine(NCI)
Last update 16 May 2025
Overview
Basic Info
Drug Type Prophylactic vaccine |
Synonyms- |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with WT-1 analog peptide vaccine(NCI)NCT00398138
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms
100 Clinical Results associated with WT-1 analog peptide vaccine(NCI)
Login to view more data
100 Translational Medicine associated with WT-1 analog peptide vaccine(NCI)
Login to view more data
100 Patents (Medical) associated with WT-1 analog peptide vaccine(NCI)
Login to view more data
1
Literatures (Medical) associated with WT-1 analog peptide vaccine(NCI)01 Oct 2010Cancer immunology, immunotherapy : CIIQ2 · MEDICINE
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
Q2 · MEDICINE
Article
Author: Andrew B. Brown ; Lee M. Krug ; Hao Li ; Tatyana Korontsvit ; Peter Maslak ; Victoria Zakhaleva ; Sara Bekele ; David A. Scheinberg ; Tao Dao ; William Travis ; Leslie Tyson ; Jedd Wolchok ; Jianda Yuan
BACKGROUND:
The transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis. Using computer prediction analysis we designed analog peptides derived from WT1 sequences by substituting amino acids at key HLA-A0201 binding positions. We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1.
METHODS:
Therapy consisted of six subcutaneous vaccinations administered with Montanide adjuvant on weeks 0, 4, 6, 8, 10, and 12, with 6 additional monthly injections for responding patients. Injection sites were pre-stimulated with GM-CSF (70 mcg). Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells.
RESULTS:
Nine patients with MPM and 3 with NSCLC were vaccinated, with 8 patients receiving at least 6 vaccinations; in total, 10 patients were evaluable for immune response. Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response. Stimulated T cells were capable of cytotoxicity against WT-1 positive cells. Vaccination also induced polyfunctional CD8 T cell responses.
CONCLUSIONS:
This multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity. A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.
100 Deals associated with WT-1 analog peptide vaccine(NCI)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Wilms Tumor | Phase 1 | United States | 31 Oct 2006 | |
| Acute Myeloid Leukemia | Phase 1 | United States | 01 Oct 2006 | |
| Acute Myeloid Leukemia | Phase 1 | United States | 01 Oct 2006 | |
| Mesothelioma, Malignant | Phase 1 | United States | 01 Oct 2006 | |
| Mesothelioma, Malignant | Phase 1 | United States | 01 Oct 2006 | |
| Myelodysplastic Syndromes | Phase 1 | United States | 01 Oct 2006 | |
| Myelodysplastic Syndromes | Phase 1 | United States | 01 Oct 2006 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 01 Oct 2006 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 01 Oct 2006 | |
| Peritoneal Neoplasms | Phase 1 | United States | 01 Oct 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | lyxmonqczs = gxlsketoof wqpkwfhqel (ptlinttkhf, fxmhasmgem - epevcrbncd) View more | - | 02 Mar 2016 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free